Insulet (PODD) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Insulet (PODD) overview

Insulet (PODD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,708m and operating profit of USD 474m; the year-end share price was 284.24 USD and market capitalisation was USD 20,008m. Insulet is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Insulet's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,515mFY 2025
Share price284.24 USDFY 2025 year end
RevenueUSD 2,708mFY 2025
Operating profitUSD 474mFY 2025
Net earningsUSD 247mFY 2025
Market capitalisationUSD 20,008mFY 2025 year end

About Insulet

Insulet develops, manufactures and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System and Classic Omnipod. The company also produces pods for Amgen's Neulasta Onpro kit, a delivery system intended to help reduce infection risk after intensive chemotherapy.

Generate the Insulet report

Insulet is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Insulet and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Insulet

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.